[HTML][HTML] Durable vision improvement after a single intravitreal treatment with antisense oligonucleotide in CEP290-LCA: Replication in two eyes

AV Cideciyan, SG Jacobson, AC Ho, M Swider… - American Journal of …, 2023 - Elsevier
Purpose An intravitreally injected antisense oligonucleotide, sepofarsen, was designed to
modulate splicing within retinas of patients with severe vision loss due to deep intronic c …

Durable Vision Improvement After a Single Intravitreal Treatment With Antisense Oligonucleotide in CEP290-Lca: Replication in Two Eyes

AV Cideciyan, SG Jacobson, A Ho, M Swider… - 2023 - jdc.jefferson.edu
PURPOSE: An intravitreally injected antisense oligonucleotide, sepofarsen, was designed to
modulate splicing within retinas of patients with severe vision loss due to deep intronic c …

[HTML][HTML] Durable vision improvement after a single intravitreal treatment with antisense oligonucleotide in CEP290-LCA: Replication in two eyes

AV Cideciyan, SG Jacobson, AC Ho… - American Journal of …, 2023 - ncbi.nlm.nih.gov
Purpose An intravitreally injected antisense oligonucleotide, sepofarsen, was designed to
modulate splicing within retinas of patients with severe vision loss due to deep intronic c …

Durable vision improvement after a single intravitreal treatment with antisense oligonucleotide in CEP290-LCA: Replication in two eyes

A Cideciyan, S Jacobson, A Ho, M Swider… - American Journal of …, 2023 - europepmc.org
Purpose An intravitreally injected antisense oligonucleotide, sepofarsen, was designed to
modulate splicing within retinas of patients with severe vision loss due to deep intronic c …

Durable vision improvement after a single intravitreal treatment with antisense oligonucleotide in CEP2 90-LCA: Replication in two eyes

AV Cideciyan, SG Jacobson, AC Ho… - American journal …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose An intravitreally injected antisense oligonucleotide, sepofarsen, was designed to
modulate splicing within retinas of patients with severe vision loss due to deep intronic c …

Durable vision improvement after a single intravitreal treatment with antisense oligonucleotide in CEP290-LCA: Replication in two eyes.

AV Cideciyan, SG Jacobson, AC Ho… - American Journal of …, 2023 - europepmc.org
Purpose An intravitreally injected antisense oligonucleotide, sepofarsen, was designed to
modulate splicing within retinas of patients with severe vision loss due to deep intronic c …